DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART III

12-28-2021 Blog Posts

Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual Despite unprecedented attention on the crisis of prescription drug affordability, Big Pharma maintained the industry’s profits-over-people approach in 2021. From repeatedly hiking drug prices, engaging in anti-competitive tactics to undermine competition, price-gouging patients and taxpayers for unproven treatments and pushing debunked innovation rhetoric to oppose drug pricing […]

DOSE OF REALITY: OVERSIGHT REPORT EXPOSES BIG PHARMA’S EGREGIOUS PRICING & ANTI-COMPETITIVE TACTICS — DEBUNKS INNOVATION RHETORIC

12-12-2021 Blog Posts

Investigation Finds Big Pharma Hiked Prices More Than 250 Times On Just 12 Top Drugs — Shielded Those Drugs From Competition For Combined 300 Years With 600 Patents On Friday, the U.S. House Committee on Oversight and Reform released a comprehensive report detailing Big Pharma’s egregious pricing and anti-competitive practices. The report is the culmination […]

SECOND OPINION: BIG PHARMA DOUBLES DOWN ON BLAME GAME STRATEGY AMID UNPRECEDENTED MOMENTUM TO LOWER RX PRICES

12-3-2021 Blog Posts

New PhRMA Ad Campaign Aims to Dodge Accountability, Push Pharma-Backed Rebate Rule That Would Hike Health Care Premiums, Boost Drug Company Profits The pharmaceutical industry is doubling down on a misleading blame game strategy meant to deflect accountability for the industry’s own egregious practices amid unprecedented momentum in Washington to lower prescription drug prices. A […]

BIG PHARMA WATCH: UNJUSTIFIED PRICE HIKES ON JUST SEVEN BRAND NAME DRUGS COST U.S. $1.6 BILLION IN 2020

11-16-2021 Blog Posts

New Analysis Underscores How Big Pharma’s Price Increases Cost The American Health System and Are Disconnected from Any Actual Innovation A new analysis from the Institute of Clinical and Economical Review (ICER) finds that brand name drug makers’ price hikes on just seven drugs cost the U.S. an additional $1.67 billion in 2020. ICER’s most […]

BIG PHARMA EARNINGS WATCH: ASTRAZENECA

11-15-2021 Blog Posts

AstraZeneca’s Q3 Earnings Report Shows Pandemic Price Hikes Profitable for Brand Name Drug Maker A late third-quarter earnings report from brand name drug makers AstraZeneca shows once again that the pandemic has proven hugely profitable for Big Pharma. AstraZeneca followed other Big Pharma giants that performed well in the third quarter of the year after […]

BIG PHARMA EARNINGS WATCH: SANOFI, ABBVIE, PFIZER & AMGEN

11-9-2021 Blog Posts

New Round of Q3 Earnings Reports Continue to Show Big Pharma Profits Buoyed By Pandemic Price Hikes Another round of third quarter earnings reports from Big Pharma giants Sanofi, AbbVie, Pfizer and Amgen demonstrate that the pharmaceutical industry continues to ride high on big profits. All four brand name drug makers topped Wall Street expectations […]

BIG PHARMA WATCH: BIG PHARMA SPENDS $263M ON LOBBYING, CAMPAIGN DONATIONS FIGHTING SOLUTIONS TO LOWER RX PRICES

11-4-2021 Blog Posts

New Analysis Highlights How Big Pharma Uses Limitless Resources, Fueled by Blockbuster Profits, to Fight Solutions That Would Help Americans Afford Their Medications In case you missed it: A new report showcases just how far Big Pharma has gone this year to put profits over people — by deploying vast resources from the industry’s limitless […]

BIG PHARMA EARNINGS WATCH: NOVARTIS, MERCK, GLAXO SMITH KLINE, BRISTOL-MYERS SQUIBB

11-1-2021 Blog Posts

New Q3 Earnings Reports Underscore How Price Hikes, Anti-Competitive Tactics Boost Branded Drug Company Profits Another batch of third quarter earnings reports from brand name drug makers Novartis, Merck, GlaxoSmithKline and Bristol-Myers Squibb demonstrate yet again that hiking pricing on prescription drugs is bigtime profitable for Big Pharma. All four drug makers beat Wall Street […]

ICYMI: NEW STUDY FINDS BIG PHARMA SPENT MORE ON SALES AND MARKETING THAN R&D DURING PANDEMIC

10-27-2021 Blog Posts

AHIP Study Finds Top Drug Companies’ Sales and Marketing Budgets Swamp R&D Budgets In case you missed it, America’s Health Insurance Plans (AHIP) released a new study Wednesday that found Big Pharma continued to spend more advertising and selling its products than investing in research and development (R&D) even amid unprecedented focus on the development […]

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON, ROCHE

10-22-2021 Blog Posts

First Round of Q3 Earnings Reports Show Big Pharma Companies Raking in Big Profits After Major Rounds of Pandemic Price Hikes Brand name drug makers Johnson & Johnson and Roche kicked off the first round of earnings reports from Big Pharma for the third quarter of the year this week. Both companies bested Wall Street […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.